DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk to Slash Insulin Prices by Up to 75%
▼ + stars: | 2023-03-14 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Novo Nordisk A/S is set to cut the U.S. list prices for several insulin drugs by up to 75%, the latest big drugmaker to make steep price reductions amid pressure to curb diabetes-treatment costs. Novo, one of the biggest sellers of insulin in the U.S. and around the world, said Tuesday it would cut the list price of its NovoLog insulin by 75% and the prices for Novolin and Levemir by 65% starting in January 2024.

☆ Novo Nordisk joins Lilly in plans to slash U.S. insulin prices
▼ + stars: | 2023-03-14 | by ( ) www.reuters.com time to read: +1 min

March 14 (Reuters) - Novo Nordisk (NOVOb.CO) said on Tuesday it would cut U.S. list prices for several insulin drugs by up to 75% next year, joining rival Eli Lilly as drugmakers come under pressure for high prices of the life-sustaining treatment. The moves follow President Joe Biden's Inflation Reduction Act last year that capped insulin prices for Medicare recipients at $35 per month, but that does not extend to patients without insurance. Novo will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%. The company also said it would reduce the list price of unbranded insulin products to match lowered price of respective branded insulin products. Eli Lilly and Co (LLY.N) said earlier this month that it would cut the list prices for its most commonly prescribed insulin products by 70% from the fourth quarter of this year.

☆ Novo Nordisk to cut price of insulin by up to 75% - WSJ
▼ + stars: | 2023-03-14 | by ( ) www.reuters.com time to read: 1 min

Companies Novo Nordisk A/S FollowMarch 14 (Reuters) - Drugmaker Novo Nordisk (NOVOb.CO) is planning to cut list prices for several insulin drugs by up to 75% in the United States, the Wall Street Journal reported on Tuesday, citing a senior company executive. Reporting by Bhanvi Satija in Bengaluru; Editing by Saumyadeb ChakrabartyOur Standards: The Thomson Reuters Trust Principles.

☆ How buzzy weight-loss drugs like Ozempic became the next craze in the hottest part of healthcare
▼ + stars: | 2023-03-14 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. CalibrateFirst developed to manage type 2 diabetes, GLP-1 medications regulate blood-sugar levels, which can help people curb cravings and feel fuller after eating. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.

☆ Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli Lilly
▼ + stars: | 2023-03-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk Inc. NovoLog brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Novo Nordisk, one of the world's biggest insulin makers, will cut the list price of its NovoLog insulin by 75% and the prices for Levemir and Novolin by 65%, the company said in a press release. NovoLog's list price will fall to $139.71 from $558.83 for a pack of five injection pens. The company also said it plans to reduce the list price of its unbranded insulin products to match the lowered price of each respective branded insulin. Novo Nordisk, Lilly and Sanofi control over 90% of the global insulin market.

[1/3] A pharmacist holds a bottle of the drug Eliquis, made by Bristol Myers Squibb and Pfizer, at a pharmacy in Provo, Utah, U.S. January 9, 2020. The government will launch the negotiation process in September by naming the first drugs it plans to target. "We couldn't have the other parts of the IRA without this Medicare negotiation," said Sean Dickson, director of the West Health Policy Center, a non-partisan healthcare think tank. Eliquis, which Bristol Myers (BMY.N) shares with Pfizer (PFE.N), Ibrance, and Imbruvica, sold by AbbVie and Johnson & Johnson (JNJ.N), appear on every list. Pfizer, Novo Nordisk and J&J declined to comment on the likelihood their drugs would be included in the first round of negotiations.

☆ Why buzzy weight-loss drugs are the next craze for healthcare startups
▼ + stars: | 2023-03-13 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +7 min

Healthcare companies are launching programs left and right to prescribe trendy weight-loss drugs. And Ro, a startup that prescribes and sells products like Viagra and hair-loss pills to consumers, is going all in with a program it launched in January to prescribe the weight-loss drugs to patients online. Even startups like Noom, which quietly started a program prescribing GLP-1 medications, could stand to benefit from the drugs' popularity after a tumultuous year for the startup. The weight-loss market for GLP-1 drugs is relatively new, and not everyone is on board. But for some companies, stepping into prescribing these new weight-loss medications seems to simply be the natural next step for growth.

☆ Economists warn of costs if Medicare covers new obesity drugs
▼ + stars: | 2023-03-11 | by ( Nancy Lapid | ) www.reuters.com time to read: +3 min

March 11 (Reuters) - The cost of expanding U.S. Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday. Big-selling diabetes drugs have been repurposed as obesity treatments after demonstrating weight loss of more than 20% in clinical trials. While they are far more effective than older drugs, lifetime use might be required to keep lost weight off. But should the bipartisan The Treat and Reduce Obesity Act get reintroduced and passed by Congress, Medicare will be compelled to cover drugs for weight loss. The Medicare health program covers more than 60 million Americans, most over age 65.

☆ I tried intermittent fasting like Elon Musk. My weight hasn't drastically changed, but the other benefits surprised me.
▼ + stars: | 2023-03-11 | by ( Sam Tabahriti | ) www.businessinsider.com time to read: +6 min

Elon Musk said last year he lost weight through intermittent fasting and lifting weights. I talked to the fitness coach Farren Morgan, who explained that intermittent fasting focuses on when — not what — you eat. "Most people find it easy to stick to this particular fasting plan because it's achievable and sustainable long-term," he said. He advised anyone considering intermittent fasting to first consult their doctor, especially if they have a preexisting medical condition. A study published in the National Library of Medicine actually found that, for some people, intermittent fasting reduced fatigue.

☆ Top 10 things the Club is watching in the stock market Tuesday: Fed's Powell, Meta, obesity
▼ + stars: | 2023-03-07 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Meta Platforms ' (META) "year of efficiency" set to continue: Bloomberg is reporting job cuts in the thousands could happen as soon as this week. WW International (WW) is higher after announcing deal to acquire the anti-obesity-focused telehealth provider Sequence. (Jim Cramer's Charitable Trust is long META, LIN, CSCO, AMZN, LLY. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ WeightWatchers is buying a company that lets you pay $99 a month to see a doctor on video and get a prescription to popular weight-loss drug Ozempic
▼ + stars: | 2023-03-07 | by ( Lakshmi Varanasi | ) www.businessinsider.com time to read: +4 min

WeightWatchers announced Monday it was buying Sequence, a clinical weight management platform. Members will get Sequence's services including telehealth visits and prescriptions for weight loss drugs like Ozempic. Through Sequence's $99-a-month subscription program, customers can schedule telehealth appointments with doctors who will prescribe weight loss and diabetes management drugs like Ozempic and Wegovy. "As science advances rapidly, we know there is a significant opportunity to improve outcomes for those using medications," WeightWatchers' CEO Sima Sistani said in a press release. Doctors are even adding the hashtags to videos that are about weight loss solutions that don't rely on those medications.

☆ Under threat, Weight Watchers enters obesity drug space. Here's what it means for the stock
▼ + stars: | 2023-03-07 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

The company's sales have been in a steady multiyear decline after an attempt to de-emphasize weight loss and focus on wellness failed miserably. WW 1Y mountain The parent of Weight Watchers has seen its market value shrink as sales have dropped for several years. Another drug, Eli Lilly's Mounjaro, adds a second incretin hormone to the mix and has been shown to be even more successful with weight loss. This trend could provide an opportunity for the core Weight Watchers brand and its focus on behavior modification. That scenario assumes Weight Watchers continues to see membership erosion, while cost controls help minimize margin compression.

☆ Workers are clamoring for pricey new weight-loss drugs like Ozempic. Companies are grappling with how to respond.
▼ + stars: | 2023-03-06 | by ( ) www.businessinsider.com time to read: +10 min

Companies that pay for workers' health insurance are grappling with how to cover the pricey drugs. Medicare, the federal program that provides health coverage for people 65 and older, doesn't cover weight-loss drugs. ArcBest already has a program to help workers lose weight through behavior changes and nutrition. Krutsch said he wants to build on that, covering the weight-loss drugs Wegovy and Saxenda for employees who aren't able to lose weight without medication. The new weight-loss drugs were in short supply in 2022, and that gave employers time to figure out how to handle them, he said.

☆ Jim Cramer's Investing Club meeting Friday: Costco, Eli Lilly, Apple
▼ + stars: | 2023-03-03 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Stick with Costco Watch Eli Lilly Own Apple 1. Morgan Stanley predicted the results could lead to a 5% to 10% upside for both Novo and Eli Lilly shares. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Europe will lose out on medical innovation if draft EU reforms pass -Novo Nordisk CEO
▼ + stars: | 2023-03-02 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

LONDON, March 2 (Reuters) - Europe will lose out to countries like the U.S. and Japan on new medical research, trials and treatments unless draft rules reforming the European pharmaceutical landscape change, the CEO of Danish drugmaker Novo Nordisk (NOVOb.CO) warned on Thursday. It says drugs need to reach patients more quickly and in all European nations. Novo's Lars Jorgensen lamented that without changes to the current draft, his company would be forced to research, test and bring products in its pipeline to market in the United States and elsewhere, instead of in Europe. A lose, lose, lose," he said in an interview. The Commission's current draft was leaked in Brussels last month and will likely change even before debate in the European parliament and among governments.

☆ Clinics are trying to sell trendy weight-loss injections by flooding TikTok with videos about semaglutide
▼ + stars: | 2023-03-02 | by ( Sindhu Sundar | Alex Bitter | ) www.businessinsider.com time to read: +9 min

The video, which has nearly 60,000 likes, is among a proliferation of TikTok posts tagged with the names of semaglutide weight-loss drugs, including Wegovy and Ozempic. "What drives the video to go viral is if you can generate some kind of discussion," he told Insider. Unlike official ads, partnerships, or promotions, TikTok posts receive little oversight from government agencies or medical boards. All four said the TikTok posts are driving an influx of patients to their clinics. Oden told Insider that her videos are "drumming up quite a bit of new business" among patients of all ages.

Eli Lilly, along with Sanofi (SASY.PA) and Novo Nordisk (NOVOb.CO) make up 90% of the U.S. market for insulin. Biden, a Democrat, on Tuesday called on Congress and other manufacturers to lower the price of insulin as Lilly had done. The list price for Lispro, a cheaper version of its Humalog insulin, is currently $82.41 for 100 units/mL vials. List prices for drugs often differ from what patients actually pay, including after insurance and other assistance programs. Ricks said the company's insulin price cuts had been planned for some time and were accounted for in Eli Lilly's December financial forecast, which projected 2023 revenue of at least $30.3 billion.

☆ Lilly to cut U.S. insulin prices by 70% from fourth quarter
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +2 min

March 1 (Reuters) - Eli Lilly and Co (LLY.N) will cut list prices by 70% for its most commonly prescribed forms of insulin, Humalog and Humulin, beginning from the fourth quarter of this year, the drugmaker said on Wednesday. Around 8.4 million of the 37 million people in the United States with diabetes use insulin, according to the American Diabetes Association. Eli Lilly, along with Sanofi (SASY.PA) and Novo Nordisk (NOVOb.CO) make up 90% of the U.S. market for insulin. Drugmakers had previously priced insulin at more than $275 a vial, representing a 1,200% increase in price over the past 20 years, according to the advocacy group Insulin Initiative. Reporting by Bhanvi Satija in Bengaluru; Additional reporting by Susan Heavey, Editing by Arun KoyyurOur Standards: The Thomson Reuters Trust Principles.

☆ Insulin cuts make drug prices a little less bazaar
▼ + stars: | 2023-03-01 | by ( ) www.reuters.com time to read: +2 min

If drug companies don’t play along, insurance companies will go elsewhere. The list price of Sanofi’s (SASY.PA) insulins rose 143% between 2012 and 2021, but the net price fell 54%. Amgen (AMGN.O) offered an autoimmune disease drug earlier this year with two prices. American politicians have been pressuring drug companies to lower prices, and President Joe Biden welcomed the move. In theory, lower list prices mean everyone pays less out of pocket at the pharmacy.

☆ This biotech startup has a chance to grab a piece of the lucrative obesity drug market, analysts say
▼ + stars: | 2023-02-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Enter biotech startup Structure Therapeutics , which is hoping to change that regimen with oral GLP-1 formulations for obesity and type 2 diabetes treatment. The stock rallied 73% in its first day of trading, but has pulled back in the weeks since its debut. Novo Nordisk's Wegovy and Ozempic are currently on the market and approved to treat obesity and type 2 diabetes. BMO was among the group of investment banks acting as joint book runners for Structure's IPO. (Jefferies was the lead book runner in Structure's IPO.)

☆ What Happens When You Stop Taking Ozempic?
▼ + stars: | 2023-02-27 | by ( Alex Janin | ) www.wsj.com time to read: 1 min

The popularity of Ozempic, used to lose weight or manage diabetes, has surged in recent months. Hundreds of thousands of people take Wegovy or Ozempic to lose weight or manage diabetes. The drugs’ main ingredient is semaglutide. It was originally prescribed for long-term diabetes management and attracted widespread attention because it can spur significant weight loss. Sales of Wegovy, the brand of semaglutide approved for weight loss in 2021, reached nearly $900 million in 2022, according to Novo Nordisk , the pharmaceutical company that manufactures both brands.

☆ Lightning Round: I like PENN because gambling is hot again
▼ + stars: | 2023-02-24 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: I like PENN because gambling is hot againMad Money host Jim Cramer takes calls on all manner of stocks, including Penn Entertainment, Novo Nordisk, Energy Transfer, Take-Two Interactive, Chewy, Palantir and Axcelis Technologies.

☆ Strategist says it's the 'last phase' of the bear market — and names 3 stocks to buy right now
▼ + stars: | 2023-02-23 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Stocks are in the "last phase" of the bear market — and investors should look forward to the second half of 2023, one analyst says. "We're sort of in the last phase of the bear market," said James Demmert, chief investment officer at Main Street Research. He pointed to another sign that the bear market is nearing its end: terminal rate estimates are rising and staying high for longer. Markets rallied at the start of the year, but Demmert said that was just another bear market rally. One of them is pharmaceutical firm Novo Nordisk , which he says is "a good example of what you want to own in a bear market."

Around 8.4 million of the 37 million people in the United States with diabetes use insulin, according to the American Diabetes Association (ADA). They tried, and failed, to extend the benefit to everyone with health insurance when they were voting on the IRA. Without Congressional approval, the Biden administration cannot impose the cap on private insurance plans and is unlikely able to create a subsidy for the uninsured, experts said. Some Medicaid plans for low-income individuals and private insurance plans also cap the monthly cost of insulin at $35. It is unclear if his proposal would include those without health insurance, who often have to pay the full price for the life-sustaining drug.

☆ Novo Nordisk CEO on safety concerns associated with off-label use of diabetes drugs
▼ + stars: | 2023-02-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO on safety concerns associated with off-label use of diabetes drugsCNBC's Meg Tirrell joins 'Closing Bell' to report on rapid prescription growth for diabetes medicine, celebrities using Ozempic and Wegovy for weight loss and the safety related to broad use of medicines.

Search resuls for: "nordisk"

25 mentions found